Rapid Micro Biosystems (RPID) Capital Expenditures Growth (3y) (2023 - 2026)

Rapid Micro Biosystems (RPID) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capex Growth (3y) (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn 1.64%
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 8.49%
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 8.89%
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 16.83%
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn 1.81%
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 0.84%
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 2.15%
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 7.57%
9 Smith & Nephew 25.80 Bn 25.22 Bn - -
10 Rapid Micro Biosystems 90.41 Mn 80.98 Mn 371,000.00 -74.22%

Historic Data

Download Data
DateValue
Mar 31, 2026 -74.22%
Dec 31, 2025 50.38%
Sep 30, 2025 -50.26%
Jun 30, 2025 50.18%
Mar 31, 2025 -48.63%
Dec 31, 2024 6.72%
Sep 30, 2024 -66.14%
Jun 30, 2024 -60.78%
Mar 31, 2024 32.58%
Dec 31, 2023 -37.49%
Sep 30, 2023 59.03%